R-Biopharm AG acquires a majority interest in Trilogy Analytical Laboratory
Darmstadt, Germany (PRWEB) April 17, 2010 -- R-Biopharm AG, a leading developer of test solutions for clinical diagnostics and food and feed safety, has announced today that the company has purchased a majority ownership position in Trilogy Analytical Laboratory, Inc. based in Washington, Missouri.
Founded in 1999, Trilogy Analytical is considered the premier commercial testing laboratory for the detection of mycotoxins and other contaminants for food and feed safety. Trilogy’s current facility has expanded into a 22,000 sq. ft. state of the art laboratory facility that employs 28 people. Trilogy’s analytical technology includes LC-MS-MS, HPLC and GC-MS. In addition, Trilogy offers a consumable product line that includes purification columns, chromatography standards and certified reference materials for use in the detection of mycotoxins.
“The management team and the senior technical staff will remain in place and Trilogy will continue to operate independently.” according to Dr. Ralf Dreher, Managing Director of R-Biopharm AG. “Trilogy’s name and reputation are synonymous with analytical excellence and the retention of Trilogy’s management team was mandatory for our long term strategic plans for expansion into the laboratory service business that will also support our diagnostic test kits. Trilogy is a welcome addition to the R-Biopharm Group”.
R-Biopharm AG currently has 13 subsidiary companies and distributes its products in more than 120 countries. R-Biopharm, Inc the US subsidiary will relocate and combine its facilities and operations with Trilogy in Washington, MO., although the two companies will continue to operate independently. “It’s important for Trilogy to maintain independence as a reference laboratory” said Kurt Johnson, President of R-Biopharm, Inc. “Even though R-Biopharm Group owns a majority interest in Trilogy they must maintain a level of trust and ensure confidentiality with their clients”.
“R-Biopharm’s commitment to allow us to continue to operate under the Trilogy brand and their engagement of our long term employees was instrumental in our decision to partner with R-Biopharm”, said Carrie Maune, President of Trilogy Analytical. “And although we had discussions with several other fine companies that had an interest in acquiring our business, the long term growth, expansion and independence of Trilogy was paramount in our decision process. R-Biopharm’s vast network of subsidiary companies and distributors will immediately expand our potential customer base worldwide”.
R-Biopharm is a leading developer of test solutions for clinical diagnostics and food & feed safety analysis. R-Biopharm assays offer high precision and accuracy, key requirements where patient, consumer and animal health are at risk. R-Biopharm has earned high accolades for its innovation and business performance. R-Biopharm’s industry leading technology has earned the company international recognition by being nominated as a finalist for 'Ernst & Young Entrepreneur of the Year in 2004, 2005, 2006 and 2009. R-Biopharm was also recognized in 2004 and 2005 after being placed in the 'Technology Text **
Read the full story at http://www.prweb.com/releases/2010/04/prweb3883244.htm.
Copyright©2010 Vocus, Inc.
All rights reserved